Clinical Trials

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Prostatic Neoplasms

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

48 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT01140373 2026-01-15

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

13 enrolled

Prostatic Neoplasms

NCT06854250 2026-01-13

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

Phase 2 Recruiting

104 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03873805 2025-06-26

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

14 enrolled 14 charts

Prostatic Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT04633148 2024-04-23

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

16 enrolled

Prostatic Neoplasms

NCT02995330 2024-02-13

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

3 enrolled 8 charts

Prostatic Neoplasms

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

BreastGenitourinaryGynecologic

10 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT05732948 2023-11-29

PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

Phase 1 Unknown

12 enrolled

Prostatic Neoplasms

NCT01093183 2023-09-13

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Phase 1/2 Terminated

25 enrolled 8 charts

Prostatic Neoplasms

NCT04227275 2023-08-21

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

16 enrolled

Prostatic Neoplasms

NCT02390063 2020-02-10

Vaccination in Prostate Cancer (VANCE)

40 enrolled

Prostatic Neoplasms

NCT02423928 2019-10-25

CryoIT

18 enrolled

Prostatic Neoplasms

NCT01420965 2019-07-10

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

Phase 2 Terminated

7 enrolled 7 charts

Phase EARLY_PHASE1 Terminated

Prostatic Neoplasms

NCT00499733 2019-01-18

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

19 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Osteosarcoma, Tongue Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Small Cell Lung Carcinoma, Intraocular Lymphoma

NCT01303705 2018-08-29

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

13 enrolled

Prostatic Neoplasms

NCT01496131 2018-03-09

Tecemotide (L-BLP25) in Prostate Cancer

Phase 2 Completed

28 enrolled 9 charts

Prostatic Neoplasms

NCT00753220 2014-11-04

CRITICAL

Phase 1/2 Terminated

7 enrolled 4 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00176605 2014-05-20

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Phase 2 Completed

15 enrolled 7 charts

Prostatic Neoplasms

NCT00005960 2013-12-04

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Unknown

Pain, Prostatic Neoplasms

NCT00381173 2013-05-14

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing